GlassScriptPhysician profile
Lawrence M Richman
NPI 1770709933
$1,472.65
in general payments reported to CMS, 2019-2025
29 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $114 · 2021: $178 · 2022: $199 · 2023: $251 · 2024: $277 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $135.38 | 2021-2024 | Sapien 3 Ultra Resilia |
| Amgen INC. | $132.76 | 2019-2023 | Repatha |
| Abbvie INC. | $125.64 | 2021-2023 | |
| Heartflow, INC. | $116.17 | 2024-2025 | |
| Lilly USA, LLC | $90.46 | 2019-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $73.33 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $65.76 | 2019-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $62.75 | 2019-2022 | |
| Genzyme Corporation | $59.70 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $53.41 | 2022 | |
| Novo Nordisk INC | $50.87 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.22 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.05 | 2024 | Xifaxan |
| Pfizer INC. | $44.90 | 2023-2025 | |
| Avanos Medical | $36.89 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $34.75 | 2024 | |
| Sanofi Pasteur INC. | $32.08 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.93 | 2019 | |
| Kyowa Kirin, INC. | $26.23 | 2023 | Crysvita |
| Esperion Therapeutics, INC. | $24.34 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $24.10 | 2025 | |
| Eisai INC. | $23.34 | 2024 | |
| Sumitomo Pharma America, INC. | $21.00 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $20.96 | 2019 | |
| Boston Scientific Corporation | $20.44 | 2025 | Watchman Flx |
| Arbor Pharmaceuticals, INC. | $20.22 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.88 | 2020 | |
| Currax Pharmaceuticals LLC | $17.34 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $16.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Richman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.